GPC Biotech AG Announces Election of Donald Soltysiak to Supervisory Board

MARTINSRIED/MUNICH, Germany, May 25 /PRNewswire-FirstCall/ -- Princeton, N.J. -- GPC Biotech AG announced today that Donald Soltysiak was elected to its Supervisory Board at the Company's Annual Shareholders Meeting held in Munich earlier today. Mr. Soltysiak is succeeding Dr. Prabhavathi Fernandes, whose term ended with today's Shareholders Meeting.

Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer said: "I would like to express my heartfelt appreciation to Dr. Fernandes for her important contributions over the last four years on GPC Biotech's Supervisory Board. I am deeply grateful for her guidance and support during a time of such significant change and growth for our Company."

"On behalf of the Supervisory Board, I would also like to warmly thank Dr. Fernandes for her dedication and support during her tenure on the Board," said Jurgen Drews, M.D., Chairman of the GPC Biotech Supervisory Board. "As a successful entrepreneur and leader in the biopharmaceutical industry, her insights have been extremely valuable."

Dr. Drews continued: "As GPC Biotech moves forward in the next phase of its corporate development, it is with great delight that I welcome Don Soltysiak on our Supervisory Board. He is a highly experienced senior pharmaceutical sales executive who led several successful launches of blockbuster oncology drugs, including Taxol and Paraplatin. His advice will be invaluable as GPC Biotech prepares for the commercialization of its first drug."

"I am excited to have the opportunity to join the GPC Biotech Supervisory Board as the Company moves into its commercialization stage," said Donald Soltysiak. "I look forward to assisting the Company as it advances."

Donald Soltysiak was at Bristol-Myers Squibb for more than 30 years, serving for 16 years as Senior Vice President of Sales for the U.S. oncology division. He was responsible for several successful product launches of key oncology drugs, including Paraplatin(R) (carboplatin) and Taxol(R) (paclitaxel). Upon his retirement in 2003, Bristol-Myers Squibb created the Donald J. Soltysiak Sales Leadership Award, which is awarded annually to an outstanding oncology sales manager. He is now a consultant to the biopharmaceutical industry and has served as an advisor for several major oncology product launches.

Dr. Jurgen Drews and Dr. Metin Colpan, whose terms also ended today, were re-elected to the Supervisory Board. All other agenda items were also adopted by today's Annual Shareholders Meeting. For more information about the results, please visit the Investor Relations/Shareholders Meeting section of the Company's Web site at http://www.gpc-biotech.com.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients whose prior chemotherapy has failed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany), and has a wholly owned U.S. subsidiary headquartered in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at http://www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech AG, including statements about the status of the FDA review process. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward- looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

Taxol(R) (paclitaxel) is a registered trademark of Bristol-Myers Squibb Company

Paraplatin(R) (carboplatin) is a registered trademark of Bristol-Myers Squibb Company

GPC Biotech

CONTACT: Martin Braendle, Director, Investor Relations & CorporateCommunications, +49-0-89-8565-2693, ir@gpc-biotech.com, In the U.S.: LaurieDoyle, Director, Investor Relations & Corporate Communications,+1-609-524-5884, usinvestors@gpc-biotech.com, both of GPC Biotech AG; InEurope: Brian Hudspith of Maitland, +44-0-20-7379-5151,bhudspith@maitland.co.uk; In the U.S.: David Schull of Russo Partners, LLC,+1-212-845-4271, david.schull@russopartnersllc.com

MORE ON THIS TOPIC